HONG KONG Xian, China-based Yufan Biotechnologies Co. Ltd. has partnered with Pittsburgh-based Abound Bio Inc. to discover and develop antibodies directing CAR T cells against cancer targets.
The three-year partnership will see the two companies incorporate antibodies for novel cancer targets into the enhanced, HPK1 (hematopoietic progenitor kinase 1)-inhibited CAR T-cell platform, they said. The agreement covers 10 cancer targets, including difficult to treat solid tumors such as liver cancer, Abounds CEO John Mellors told BioWorld.
Although both companies declined to reveal financial details, Mellors said, I calculate that Yufans technology added to Abounds antibodies gives a value greater than two." Yufan declined to comment for the article, but CEO Yan Zhang said, "The partnership with Abound will improve CAR T-cell products for cancer therapy.
The two companies will also share expertise and any potential commercial upside, as well as inventorship and development rights. Yufan definitely benefits, both financially and non-financially, particularly via development rights in China, Mellors said.
The companies will conduct preclinical, then clinical testing of the new CAR T cells against solid tumors, with trials expected to start in the first or second quarter of 2021, Mellors said. They will target the greater China market initially, with the rest of the world to follow. No other firms have been targeted as future partners yet.
Academic roots
The partnership between Yufan and Abound started with an academic collaboration between the National Cancer Institute and Tsinghua University, based on the work led by the universitys professor of pharmaceutical science, Xuebin Liao, who co-founded Yufan along with Zhang. That work demonstrated that HPK1 promotes T-cell exhaustion through NFkB-Blimp1 activation, and that blocking HPK1, via either gene knockout or small-molecule inhibitors, improves CAR T-cell immunotherapy.
Yufan was founded in July 2016 as part of the Xi'an Hi-tech Industries Development Zone Central Organization Departments Thousand Talents program. It focuses on upstream technology development, services and antibody screening for immuno-oncology therapy. The company is developing CAR T cells with a deleted HKP1 gene to prevent cell exhaustion, with a first-in-human clinical study of the XYF-19 HPK1 knockout CD19 CAR T product currently underway in patients with relapsed or refractory CD19+ leukemia or lymphoma.
Other projects include CAR T-cell therapy, CAR T-cell GMP production, immune cell gene editing CRISPR/Cas9 technology, a phage antibody library, phage display technology, and the buildout of a human antibody screening platform. The company is currently collaborating with the Air Force Military Medical Universitys Xijing Hospital on an investigational CAR T-cell therapy.
Yufan plans to invest 100 million (US$14.72 million) to build manufacturing facilities for CAR T-cell therapies to treat refractory and relapsed leukemia and lymphoma and expects to generate annual sales of between 200 million to 400 million once those candidates reach market.
Across the Pacific, Abound is an early stage biotechnology company developing antibody-based biological therapeutics for cancer and infectious diseases.
One infectious disease that the company is concentrating on is COVID-19, with the number of global cases topping 35 million as of Oct. 5, according to Johns Hopkins University data. An Abound team led by Mellors and the companys chief scientific officer, Dimiter Dimitrov, discovered human monoclonal antibodies with neutralizing activity in the laboratory against SARS-CoV-2, the virus that causes COVID-19, from antibody libraries.
Although the antibodies have proved effective in low doses in mouse and hamsters, human trials have not yet started. However, the antibodies are ready for testing in CAR T cells in preclinical models, and we hope to rapidly progress to clinical studies, Mellors said.
The company is currently proceeding with production and clinical development for regulatory approval and commercialization in the MENA and ASEAN regions, clinching an agreement with Saudi-U.S. joint venture Saudivax earlier in the year.
The Yufan-Abound partnership also aims to tap the lucrative T-cell market, which was valued at $2.7 billion in 2017 and is expected to reach $8.21 billion in 2025, growing at a compounded annual growth rate (CAGR) of 14.9% between 2017 and 2025, according to Frost & Sullivans report Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025.
Amendments in regulatory and reimbursement policies, as well as the implementation of conditional approval policies for regenerative medicine, will further drive the market by expediting product launches, Aarti Chitale, Frost & Sullivan senior research analyst for transformational health, wrote. Additionally, improvements in cell culturing techniques alongside the use of different stem cells such as adipose-derived stem cells, mesenchymal stem cells, and induced pluripotent stem cells will strengthen the market with superior treatment options for non-oncological conditions such as neurological, musculoskeletal, and dermatological conditions, she added.
See original here:
Yufan inks deal with Abound to develop antibodies directing CAR T cells against cancer targets - BioWorld Online
- Advances in regenerative medicine-based approaches for skin ... - March 9th, 2025
- Regenerative Medicine: Case Study for Understanding and Anticipating ... - March 9th, 2025
- Top 3 Grants in Regenerative Medicine: February 2025 - RegMedNet - March 9th, 2025
- Editorial: Tissue Engineering and Regenerative Medicine: Advances, Controversies, and Future Directions by Frontiers in Bioengineering and... - March 9th, 2025
- Malaysia To Host 7th World Conference On Exercise And Regenerative Medicine - BERNAMA - March 9th, 2025
- Advancing Regenerative Medicine: A Comprehensive Outlook on the Global Cell Therapy Market - openPR - March 9th, 2025
- Worlds First 3D-Printed Penis Implant Successfully Restores Function in Pigs and Rabbits - The Daily Galaxy --Great Discoveries Channel - March 9th, 2025
- AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinsons disease investigational gene therapy - Bayer - February 24th, 2025
- What is Regenerative Medicine? | Regenerative Medicine | University of ... - February 24th, 2025
- The quest for a communication device that tells cells to regenerate the body - Big Think - February 24th, 2025
- Transforming the future of regenerative medicine - Reuters - February 24th, 2025
- Breakthrough Alzheimer's Treatment Gets Official WHO Recognition - Major Milestone for Rare Disease Therapy - StockTitan - February 24th, 2025
- Regenerative Medicine Pioneer with 35-Year Track Record Takes Scientific Helm at ZEO ScientifiX - StockTitan - February 24th, 2025
- 101 Guide to Regenerative Medicine Types | Applications, Challenges - February 7th, 2025
- Regenerative Medicine | What is it? | ASCPM - February 7th, 2025
- Regenerative medicine and advanced therapy | NIST - February 7th, 2025
- Therapeutic Reprogramming toward Regenerative Medicine - February 7th, 2025
- Novel living biomaterial aims to advance regenerative medicine - February 7th, 2025
- UC Irvine-led discovery of new skeletal tissue advances regenerative ... - February 7th, 2025
- Top 3 Grants in Regenerative Medicine: January 2025 - RegMedNet - February 7th, 2025
- Advancements in lung regeneration: from bench to bedside - February 7th, 2025
- Entos Pharmaceuticals Awarded $4 Million USD in Funding from the California Institute for Regenerative Medicine (CIRM) for its Congenital Generalized... - February 7th, 2025
- Adia Nutrition Officially Enters $15.1 Billion Global Stem Cell Market with Domestic Treatments by Successful Opening of First Florida Location -... - February 7th, 2025
- Cell therapy weekly: iPSC therapy IND for Phase III trial cleared - RegMedNet - February 7th, 2025
- Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz - EIN News - February 7th, 2025
- Placental Stem Cell Therapy Solution Market Size And Booming - openPR - February 7th, 2025
- Stem Cells Applications in Regenerative Medicine and Disease ... - December 6th, 2024
- Ageing of stem cells reduces their capacity to form tumours - Nature.com - December 6th, 2024
- Master of Science in Regenerative Medicine and Entrepreneurships FUSION program information session - The Daily | Case Western Reserve University - December 6th, 2024
- BioRestorative Therapies Announces Notice of Allowance of - GlobeNewswire - December 6th, 2024
- Stem Cell Therapy Strategic Business Report 2024 - - GlobeNewswire - December 6th, 2024
- University of Colorado Anschutz Medical Campus-Led Team Receives Up to $46 Million to Develop Innovative Treatment to Cure Blindness - University of... - December 6th, 2024
- Affimed Announces Acimtamig and AlloNK Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug... - December 6th, 2024
- Navigating the hope and hype of regenerative medicine - October 14th, 2024
- Cell and Gene Therapy Investment Ticks Up After Hard Few Years - BioSpace - October 14th, 2024
- Crackdowns on Unproven Stem Cell Therapies Worked Abroad - Medpage Today - October 14th, 2024
- How Regenerative Medicine can help you get out of pain without surgery - WJLA - October 14th, 2024
- Regenity Biosciences Receives 510(k) Clearance for RejuvaKnee, a Groundbreaking Regenerative Meniscus Implant Device to Redefine the Standard of Care... - October 14th, 2024
- Buy, Sell, Hold: Cell and Gene Therapy - BioPharm International - October 14th, 2024
- Mayo Clinic offers unique regenerative medicine procedure for knee and ... - September 13th, 2024
- Regenerative Medicine to the Rescue - Cleveland Clinic - September 13th, 2024
- Regenerative medicine applications: An overview of clinical trials - September 13th, 2024
- The Progression of Regenerative Medicine and its Impact on Therapy ... - September 13th, 2024
- Immune cell injection significantly boosts healing of bone, muscle & skin - September 13th, 2024
- Regenerative Medicine Foundation - September 13th, 2024
- BridgeBio Receives FDAs Regenerative Medicine Advanced Therapy (RMAT ... - September 13th, 2024
- Tissue engineering and regenerative medicine approaches in colorectal ... - September 13th, 2024
- Tubular scaffolds boost stem cell-driven bone regeneration in skull defects - Phys.org - September 13th, 2024
- Finding the right path(way) to reduce fat accumulation in the liver - Medical University of South Carolina - September 13th, 2024
- NAMRU EURAFCENT Signs Agreement with Egypt Center for Research and Regenerative Medicine - DVIDS - September 13th, 2024
- BridgeBio Receives FDAs Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program - StockTitan - September 13th, 2024
- BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and... - September 13th, 2024
- Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate - Yahoo Finance - September 13th, 2024
- Aging is associated with functional and molecular changes in distinct hematopoietic stem cell subsets - Nature.com - September 13th, 2024
- Cellino Awarded $25M in Funding from the Advanced Research Projects Agency for Health (ARPA-H) - Business Wire - September 13th, 2024
- HepaTx Enters Collaboration with Mayo Clinic to Advance Cell Therapy Technology for Liver Disease to Clinical Trials - Longview News-Journal - September 13th, 2024
- Obsidian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OBX-115 for the Treatment of Advanced Melanoma -... - September 4th, 2024
- Regenerative Medicine in Orthopedic Surgery: Expanding Our Toolbox - Cureus - September 4th, 2024
- Somite.ai takes pre-seed to $10M as it eyes to become the OpenAI of stem cell biology - CTech - September 4th, 2024
- Longeveron Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS) - Yahoo... - September 4th, 2024
- Study Explores Potential Of 3D Printed Regenerative Breast Implants - Forbes - September 4th, 2024
- Nikon Announces New Image Analysis Functions to Empower Drug Discovery Research for Cancer, Neurological Disease, and Regenerative Medicine - PR... - September 4th, 2024
- Trinity researcher scores 800,000 to boost regenerative medicine - SiliconRepublic.com - September 4th, 2024
- Seeing the future: Zebrafish regenerates fully functional photoreceptor cells and restores its vision - EurekAlert - September 4th, 2024
- Regenerative Medicine Industry Projected to Surge to USD 73,084.2 Million by 2033, Growing at an 18.5% CAGR - Future Market Insights - September 4th, 2024
- What is regenerative medicine? | Northwell Health - July 2nd, 2024
- Science Saturday: A regenerative reset for aging - July 2nd, 2024
- Science Saturday: A year of new directions and advancements for ... - March 29th, 2024
- Diverse ways regenerative medicine is advancing health care - March 29th, 2024
- Stem cell-based regenerative medicine - PMC - National Center for ... - February 27th, 2024
- Regenerative medicine | NIST - February 10th, 2024
- San Jose blood stem cell donor meets 15-year-old whose life he saved in Los Angeles - The Mercury News - May 17th, 2023
- Regenerative medicine: Current therapies and future directions - April 23rd, 2023
- What Is Regenerative Medicine? | Goals and Applications | ISCRM - April 23rd, 2023
- Important Patient and Consumer Information About Regenerative Medicine ... - April 23rd, 2023
- Regenerative medicine can be a boon for those with Drug-Resistant Tuberculosis - Hindustan Times - April 23rd, 2023
- About Regenerative Medicine - Center for Regenerative ... - Mayo Clinic - April 7th, 2023
- Regenerative Medicine | National Institutes of Health (NIH) - April 7th, 2023
- Porcine Vaccine Market is estimated to be US$ 4.41 billion by 2030 with a CAGR of 7.50%during the forecast - EIN News - April 7th, 2023
- Advancing Safe and Effective Regenerative Medicine Products - March 21st, 2023